Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

The two companies will carry out a phase 2 trial of Libtayo (cemiplimab) alongside BioNTech’s mRNA cancer immunotherapy BNT111, which is designed to stimulate immune responses against four ...

In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million ... With that result, the drug has become "the first immunotherapy to show a benefit in this high-risk population ...

This news follows a recent Phase 3 trial where Keytruda®, another immunotherapy, failed to show similar benefits in the same setting. The success of Libtayo in this trial could represent a ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...